Financial Performance and Operational Growth
Anlon Healthcare Limited demonstrated strong fiscal momentum in FY26, reporting a consolidated total income of ₹172.22 Crore, a significant 42.98% increase over the previous year. This growth was mirrored in profitability, with EBITDA rising by 47.55% to ₹47.77 Crore and Profit After Tax (PAT) increasing by 41.77% to ₹29.09 Crore. The company maintained a healthy EBITDA margin target of 25-30% on a consolidated basis.
While the operating performance exceeded several internal benchmarks, the company faced challenges in working capital management, with receivable days ending at 290, significantly higher than the management's initial guidance of 180-185 days.
Management Outlook and Strategic Guidance
The management has provided a highly optimistic growth trajectory, projecting revenues to reach ₹380-400 Crore in FY27 and scaling further to ₹700-800 Crore by FY28. This rapid expansion is backed by a clear order book visibility of approximately ₹280-300 Crore for the upcoming fiscal year. To support this growth, Anlon is undertaking a substantial Capex program of ₹130 Crore.
The strategy involves launching seven new APIs in FY27 and expanding into industrial and fine chemicals. Management remains confident in meeting these targets through a combination of capacity expansion and improved pricing power, having successfully negotiated price increases with customers to offset raw material costs.
Business Overview and Integration Strategy
Anlon Healthcare is pivotally shifting its business model towards deeper vertical integration and specialized manufacturing. The recent acquisitions of Apiqo Organic and Bizotic are central to this strategy, providing backward integration capabilities that enhance supply chain resilience and potentially improve margins. The company operates across API manufacturing and Contract Development and Manufacturing Operations (CDMO).
In FY26, the CDMO segment showed progress with the dispatch of one molecule, while two others are scheduled for validation in early FY27. The product portfolio is also undergoing regulatory strengthening, with ongoing DMF filings for Ketoprofen in the United States and Dexketoprofen in Europe.
Sector Dynamics and Risk Profile
The pharmaceutical and biotechnology sector in India is experiencing a shift towards self-reliance in API sourcing, a trend Anlon is capitalizing on through its expansion. However, the industry remains sensitive to global supply chain disruptions and raw material price volatility. Anlon's management highlighted their ability to maintain margins despite these headwinds by leveraging pricing power.
A critical internal factor for the company remains its high working capital cycle. The current 290-day receivable period represents a liquidity risk that could impact the pace of future expansions if not optimized. The sector at large is trading at a PE of 40, while Anlon currently trades at a more conservative 27.08.
What to Watch
- Execution of the ₹130 Crore Capex program and its impact on production capacity by FY27.
- Management's ability to reduce working capital days from 290 toward the target range of 180-185.
- Successful commercial launch of the seven new APIs planned for the upcoming fiscal year.
- Progress of regulatory filings, specifically Ketoprofen DMF in the US and Dexketoprofen in Europe.
- Realization of the projected ₹280-300 Crore order book visibility into actual revenue for FY27.
